Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
← catalyst calendarNCT06445062 · readout in 269 d
Sponsored by Revolution Medicines, Inc. (industry) · RVMD — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
1,130estimated
Sites
32
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-05-24 | actual | When the study began enrolling |
| Primary completion | 2027-05-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-15 | estimated | The whole study's end, after follow-up |
| First posted | 2024-06-06 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Colorectal Cancer
- CRC
- Pancreatic Ductal Adenocarcinoma
- PDAC
- Gastrointestinal Cancer
- Metastatic Pancreatic Ductal Adenocarcinoma
Interventions
- Drug: RMC-6236
- Drug: mFOLFOX6 regimen
- Drug: bevacizumab
- Drug: mFOLFIRINOX regimen
- Drug: cetuximab
- Drug: gemcitabine
- Drug: nab-paclitaxel
- Drug: RMC-9805
Primary outcomes
what the primary-completion date above is the date OFAdverse events
measured Up to 3 years
Dose limiting toxicities
measured 28 days
Publications
- PMID 40056080 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · RVMD's whole pipeline · Catalyst calendar · Every registered study · What changed